Clinical breakthroughs cannot secure a market path if patients cannot tolerate the safety trade-offs.
Treatments carrying superior clinical and biological efficacy frequently face commercial and regulatory resistance if they trigger severe, intolerable toxicities or side effects.
The same conclusion keeps arriving from across the workspace's research — 1 topics independently instantiate this theme. Filter the evidence by where it came from:
A lymphoma therapy met its primary efficacy endpoint but faced severe regulatory and commercial headwinds due to a dramatic 3-to-1 death imbalance in the treatment arm.
Despite being safe, the drug’s high-stakes clinical trial failed entirely to show a functional advantage when evaluated alongside contemporary standard-of-care baseline treatments.
Numerical efficacy milestones in obesity weight loss were completely overshadowed by severe, commercially unviable gastrointestinal side effects.